Meanwhile, higher levels of SCD1 or URI were associated with worsen prognosis in p53-WT HCC patients receiving sorafenib treatment (Fig. 8i–o), while no significant correlation were found in p53-mutation patients (Supplementary Fig. 11g, h). This evidence concerns the gene SCD and hepatocellular carcinoma.